Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.95
Year High
$4.91
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
P/S ratio for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
P/S ratio as of 2023: 12.54
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.54. At the end of 2022 the company had a P/S ratio of 11.53.
P/S ratio history for Jiangsu Hengrui Medicine Co., Ltd. from 1997 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 12.54 |
| 2022 | 11.53 |
| 2021 | 12.49 |
| 2020 | 21.29 |
| 2019 | 16.54 |
| 2018 | 11.20 |
| 2017 | 11.59 |
| 2016 | 8.02 |
| 2015 | 8.58 |
| 2014 | 5.24 |
| 2013 | 5.80 |
| 2012 | 4.77 |
| 2011 | 5.06 |
| 2010 | 8.26 |
| 2009 | 7.49 |
| 2008 | 5.78 |
| 2007 | 8.81 |
| 2006 | 7.52 |
| 2005 | 1.36 |
| 2004 | 1.19 |
| 2003 | 0.87 |
| 2002 | 1.45 |
| 2001 | 2.43 |
| 2000 | 4.35 |
| 1999 | 4.67 |
| 1998 | 5.32 |
| 1997 | 6.37 |